News
07-25-2012, 05:50 AM
EntreMed, Inc., a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study.
More... (http://www.news-medical.net/news/20120725/EntreMed-commences-ENMD-2076-Phase-2-study-in-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20120725/EntreMed-commences-ENMD-2076-Phase-2-study-in-triple-negative-breast-cancer.aspx)